Group items tagged

Elemental information and data relating to the clinical trials on fatty liver disease including an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe offers a perspective on the fatty liver disease clinical trial scenario. Disease clinical trials by their phase, trial status, prominence of the sponsors pertaining to the number of trials for the key drugs for treating fatty liver disease hints at the dynamics of a particular indication in a condensed manner in addition to the commercial landscape of the major universities, institutes, hospitals or companies.

This report includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Abdominal Obesity.

Interesting info. What other meds can be taken?

As far as I know, Xenical (Orlistat) promotes weight loss by decreasing the amount of dietary fat absorbed in your intestines. You can find out more about it on the Canada Drugs site https://www.canadadrugsdirect.com/. It has to be noted, that this medication should only be used under the supervision of a trained healthcare professional.

According to diagnostic ultrasound imaging market forecasts, the global disease incidence is expected to rise and an early diagnosis of disease is the foundation for increasing survival rates. Diagnostic ultrasound imaging is the most widely used technique to achieve early detection and clinical assessment of adult and pediatric patients alike, making it a cornerstone of disease control. In the diagnostic ultrasound imaging market landscape GE Healthcare currently dominates the global diagnostic ultrasound market.

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.

With conventional corticosteroid treatment being effective in only 50-60% of patients, development of new treatment options is necessary to cover the unmet needs of the uveitis market. The market is currently dominated by corticosteroid treatment options and off-label immunosuppressive and biologic drugs. Although anterior uveitis patients constitute the major share of patients, except one, all the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. Drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile will have a significant impact on the uveitis market.

According to market forecasts, the global renal denervation market will witness significant growth over the next six years, jumping from USD 15.5 million in 2012 to USD 171.7 million by 2019, at a CAGR of 41%. This will mainly be attributable to the intervention's expected approval in major countries. It is stated that across 10 major markets in the major global economies (the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India), only the European Union has approved the use of renal denervation.